J.P. Morgan analyst Anupam Rama has maintained their neutral stance on SRPT stock, giving a Hold rating on May 7.
Claim 55% Off TipRanks
Trade SRPT with leverageAnupam Rama has given his Hold rating due to a combination of factors relating to both Sarepta’s current business and its development pipeline. He does not anticipate meaningful share appreciation in 2026 driven solely by existing commercial products, as Elevidys still requires stronger uptake despite management’s confidence in near‑term consensus and long‑term revenue potential.
At the same time, he sees 2026 as being heavily influenced by upcoming clinical readouts, including Cohort 8 of ENDEAVOR in non‑ambulatory DMD and early‑stage studies in FSHD1 and DM1, which carry significant binary risk. The company is working to mitigate safety concerns and competitive threats, but these efforts need further evidence and execution before materially changing the risk‑reward profile, leading him to balance opportunity against uncertainty with a Neutral stance.
In another report released on May 7, TD Cowen also maintained a Hold rating on the stock with a $17.00 price target.
Based on the recent corporate insider activity of 30 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of SRPT in relation to earlier this year.